

# Kristina Deligiannidis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1167669/publications.pdf>

Version: 2024-02-01

63  
papers

2,940  
citations

279798

23  
h-index

175258

52  
g-index

66  
all docs

66  
docs citations

66  
times ranked

2781  
citing authors

#	ARTICLE	IF	CITATIONS
1	Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. <i>Lancet, The</i> , 2018, 392, 1058-1070.	13.7	547
2	Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. <i>Lancet, The</i> , 2017, 390, 480-489.	13.7	311
3	Clinical phenotypes of perinatal depression and time of symptom onset: analysis of data from an international consortium. <i>Lancet Psychiatry, the</i> , 2017, 4, 477-485.	7.4	199
4	Heterogeneity of postpartum depression: a latent class analysis. <i>Lancet Psychiatry, the</i> , 2015, 2, 59-67.	7.4	198
5	A Double-blind Randomized Controlled Trial of Olanzapine Plus Sertraline vs Olanzapine Plus Placebo for Psychotic Depression. <i>Archives of General Psychiatry</i> , 2009, 66, 838.	12.3	188
6	Pharmacotherapy for Mood Disorders in Pregnancy. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 244-255.	1.4	157
7	Antidepressant use in pregnancy: a critical review focused on risks and controversies. <i>Acta Psychiatrica Scandinavica</i> , 2013, 127, 94-114.	4.5	131
8	GABAergic neuroactive steroids and resting-state functional connectivity in postpartum depression: A preliminary study. <i>Journal of Psychiatric Research</i> , 2013, 47, 816-828.	3.1	114
9	Effect of Zuranolone vs Placebo in Postpartum Depression. <i>JAMA Psychiatry</i> , 2021, 78, 951.	11.0	102
10	Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development. <i>CNS Drugs</i> , 2019, 33, 265-282.	5.9	82
11	Peripartum neuroactive steroid and $\hat{1}^3$ -aminobutyric acid profiles in women at-risk for postpartum depression. <i>Psychoneuroendocrinology</i> , 2016, 70, 98-107.	2.7	79
12	Complementary and alternative medicine therapies for perinatal depression. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2014, 28, 85-95.	2.8	72
13	Association of peripartum synthetic oxytocin administration and depressive and anxiety disorders within the first postpartum year. <i>Depression and Anxiety</i> , 2017, 34, 137-146.	4.1	69
14	Antidepressant Augmentation Using the <i>N</i> -Methyl-D-Aspartate Antagonist Memantine. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 966-973.	2.2	67
15	Resting-state functional connectivity, cortical GABA, and neuroactive steroids in peripartum and peripartum depressed women: a functional magnetic resonance imaging and spectroscopy study. <i>Neuropsychopharmacology</i> , 2019, 44, 546-554.	5.4	57
16	Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 622.	7.4	53
17	Complementary and Alternative Medicine for the Treatment of Depressive Disorders in Women. <i>Psychiatric Clinics of North America</i> , 2010, 33, 441-463.	1.3	40
18	Understanding Peripartum Depression Through Neuroimaging: a Review of Structural and Functional Connectivity and Molecular Imaging Research. <i>Current Psychiatry Reports</i> , 2017, 19, 70.	4.5	33

#	ARTICLE	IF	CITATIONS
19	Examining the relationship between perinatal depression and neurodevelopment in infants and children through structural and functional neuroimaging research. <i>International Review of Psychiatry</i> , 2019, 31, 264-279.	2.8	33
20	Expression of inflammatory markers in women with perinatal depressive symptoms. <i>Archives of Women's Mental Health</i> , 2018, 21, 671-679.	2.6	31
21	The impact of pregnancy on the pharmacokinetics of antidepressants: a systematic critical review and meta-analysis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 431-440.	3.3	31
22	White matter integrity in medication-free women with peripartum depression: a tract-based spatial statistics study. <i>Neuropsychopharmacology</i> , 2018, 43, 1573-1580.	5.4	27
23	Regulation of Arylalkylamine N-Acetyltransferase-2 (AANAT2, EC 2.3.1.87) in the Fish Pineal Organ: Evidence for a Role of Proteasomal Proteolysis. <i>Endocrinology</i> , 2001, 142, 1804-1813.	2.8	27
24	Excretion of Antipsychotics Into the Amniotic Fluid, Umbilical Cord Blood, and Breast Milk: A Systematic Critical Review and Combined Analysis. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 245-254.	2.0	22
25	Peripartum depression and anxiety as an integrative cross domain target for psychiatric preventative measures. <i>Behavioural Brain Research</i> , 2015, 276, 32-44.	2.2	21
26	Response to SARS-Covid-19-related visitor restrictions on labor and delivery wards in New York City. <i>Archives of Women's Mental Health</i> , 2020, 23, 793-794.	2.6	21
27	Therapeutic Drug Monitoring in Pregnant and Postpartum Women: Recommendations for SSRIs, Lamotrigine, and Lithium. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 649-650.	2.2	20
28	Evidence-Based Treatment of Premenstrual Dysphoric Disorder. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	18
29	Antidepressant transfer into amniotic fluid, umbilical cord blood & breast milk: A systematic review & combined analysis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 107, 110228.	4.8	18
30	A Gender Analysis of the Study of Pharmacotherapy of Psychotic Depression (STOP-PD). <i>Journal of Clinical Psychiatry</i> , 2013, 74, 1003-1009.	2.2	16
31	Longitudinal proneuroactive and neuroactive steroid profiles in medication-free women with, without and at-risk for perinatal depression: A liquid chromatography-tandem mass spectrometry analysis. <i>Psychoneuroendocrinology</i> , 2020, 121, 104827.	2.7	15
32	Cortisol response to the Trier Social Stress Test in pregnant women at risk for postpartum depression. <i>Archives of Women's Mental Health</i> , 2016, 19, 789-797.	2.6	14
33	The Prevalence of Bipolar Disorders and Association With Quality of Life in a Cohort of Patients With Multiple Sclerosis. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2017, 29, 45-51.	1.8	14
34	Complementary Health Practices for Treating Perinatal Depression. <i>Obstetrics and Gynecology Clinics of North America</i> , 2018, 45, 441-454.	1.9	13
35	Advances in pharmacotherapy for postpartum depression: a structured review of standard-of-care antidepressants and novel neuroactive steroid antidepressants. <i>Therapeutic Advances in Psychopharmacology</i> , 2022, 12, 204512532110658.	2.7	12
36	Symptom profiles of women at risk of mood disorders: A latent class analysis. <i>Journal of Affective Disorders</i> , 2021, 295, 139-147.	4.1	10

#	ARTICLE	IF	CITATIONS
37	Peripartum depression: Does risk versus diagnostic status impact motherâ€™infant bonding and perceived social support?. <i>Depression and Anxiety</i> , 2021, 38, 390-399.	4.1	10
38	Management of New Onset Psychosis in the Postpartum Period. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 1423-1424.	2.2	9
39	Long-Acting Injectable Antipsychotic Use During Pregnancy. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	9
40	Psychiatry Resident/Fellow-Initiated and -Designed Multi-Modal Psychopharmacology Curriculum for Major Depression. <i>Academic Psychiatry</i> , 2012, 36, 414.	0.9	7
41	A Collaborative, Network-Based Approach to Advance Women's Depression Research in the United States: Preliminary Findings. <i>Journal of Women's Health</i> , 2018, 27, 51-57.	3.3	7
42	Effects of Perinatal Depression and Anxiety on Labor and Delivery Outcomes. <i>Obstetrics and Gynecology</i> , 2014, 123, 82S-83S.	2.4	5
43	The physicianâ€™scientist workforce in the United States. <i>Acta Psychiatrica Scandinavica</i> , 2015, 132, 317-318.	4.5	5
44	The implications of the National Institute of Mental Health Research Domain Criteria for researchers and clinicians. <i>Acta Psychiatrica Scandinavica</i> , 2014, 130, 409-414.	4.5	4
45	Prenatal complications and neurodevelopmental outcomes in offspring: interactions and confounders. <i>Acta Psychiatrica Scandinavica</i> , 2020, 142, 261-263.	4.5	4
46	Comparison of the Use of the EPDS-3 vs. EPDS-10 to Identify Women at Risk for Peripartum Depression [3K]. <i>Obstetrics and Gynecology</i> , 2016, 127, 89S-90S.	2.4	3
47	86: Brexanolone iv efficacy in postpartum depression in three pivotal trials: montgomery-Ã’sberg depression rating scale assessment. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 220, S69-S70.	1.3	2
48	Acute Bipolar Psychosis Limited to the Course ofÃan Ectopic Pregnancy. <i>Psychosomatics</i> , 2020, 61, 799-803.	2.5	2
49	934: Phase 3, randomized, placebo-controlled trial of SAGE-217 in postpartum depression: Association between HAM-D and PHQ-9. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 222, S578.	1.3	2
50	Evaluation of Insomnia Symptoms in a Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial of Zuranolone in Postpartum Depression. <i>Biological Psychiatry</i> , 2021, 89, S91.	1.3	2
51	O21. Resting-State Functional Connectivity, Cortical Gaba and Allopregnanolone in Postpartum Depression: AÃFunctional Magnetic Imaging and Spectroscopy Study. <i>Biological Psychiatry</i> , 2019, 85, S114.	1.3	1
52	Brexanolone iv, a GABA-A receptor modulator, in postpartum depression: Pooled analysis of HAM-D sub-items. <i>European Neuropsychopharmacology</i> , 2019, 29, S63.	0.7	1
53	Insights on GABAergic Mechanism of PPD from Pivotal Studies of Brexanolone Injection and SAGE-217 [18E]. <i>Obstetrics and Gynecology</i> , 2020, 135, 54S.	2.4	1
54	Functional MRI biomarkers of peripartum psychiatric disorders. , 2020, , 181-205.		1

#	ARTICLE	IF	CITATIONS
55	Poor neonatal adaptation syndrome: Toward a clinical consensus to guide research and counseling. <i>Acta Psychiatrica Scandinavica</i> , 2022, 145, 3-5.	4.5	1
56	943. White Matter Integrity in Medication-Free Women with Peripartum Depression: Diffusion Tensor Imaging Study Using Tract-Based Spatial Statistics. <i>Biological Psychiatry</i> , 2017, 81, S381-S382.	1.3	0
57	69. Neuroactive Steroids and GABA in Peripartum Depression. <i>Biological Psychiatry</i> , 2017, 81, S28-S29.	1.3	0
58	F73. Efficacy of Brexanolone Injection in Subjects With Postpartum Depression With and Without Baseline Antidepressant Therapy: Insights From an Integrated Analysis of Three Pivotal Trials. <i>Biological Psychiatry</i> , 2019, 85, S241.	1.3	0
59	S88. Longitudinal Plasma GABAergic Neuroactive Steroid Concentrations in Postpartum Depression. <i>Biological Psychiatry</i> , 2019, 85, S330-S331.	1.3	0
60	P.308 A double-blind, randomized, placebo-controlled phase 3 study of sage-217 in postpartum depression: improvements in unidimensional measures of depression and anxiety. <i>European Neuropsychopharmacology</i> , 2019, 29, S219-S220.	0.7	0
61	P.307 Effect of zuranolone on depression and anxiety outcomes in postpartum depression in a randomized, placebo-controlled trial. <i>European Neuropsychopharmacology</i> , 2020, 40, S177.	0.7	0
62	1068: Insights on GABAergic mechanism of postpartum depression from pivotal studies of brexanolone injection and SAGE-217. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 222, S659-S660.	1.3	0
63	Rapid and Sustained Improvement in Concurrent Symptoms of Depression and Anxiety in a Post Hoc Analysis of Zuranolone Treatment in Postpartum Depression. <i>Biological Psychiatry</i> , 2021, 89, S157.	1.3	0